Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.82 |
| ▸ | RXRB | P28702 | 12/20 | 0.82 |
| ▸ | RXRG | P48443 | 12/20 | 0.82 |
| ▸ | RARB | P10826 | 7/20 | 0.82 |
| ▸ | RARG | P13631 | 7/20 | 0.82 |
| ▸ | RARA | P10276 | 5/20 | 0.82 |
| ▸ | PPARG | P37231 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357483 | 0.90 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL301213 | 0.90 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL29434832 | 0.90 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL21549712 | 0.88 | RXRA (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL1073361 | 0.87 | RXRA (0.77) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6889517 | 0.85 | RXRA (0.73) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL5533586 | 0.81 | RXRA (0.68) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL20411355 | 0.81 | RXRA (0.78) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7023688 | 0.81 | RXRA (0.71) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL13847133 | 0.80 | RXRA (0.66) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293506-A1 | TREATMENT OF AUTOIMMUNE DISEASES WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | Io Therapeutics, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-11690831-B2 | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones | Io Therapeutics, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690832-B2 | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones | IO THERAPEUTICS (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230126763-A1 | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS | Io Therapeutics, Inc. | 2023-04-27 | — | — | US | disclosed |
| US-20090203720-A1 | Methods for inhibiting cell growth | ALLERGAN, INC. | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690831-B2 | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones | RXRA, RXRB, RXRG | RXRA 1/4885RXRB 2/4885RXRG 3/4885 |
| US-20230293506-A1 | TREATMENT OF AUTOIMMUNE DISEASES WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | RXRA, RXRG, RXRB | RXRA 1/4885RXRB 3/4885RXRG 2/4885 |
| US-20230126763-A1 | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS | RXRA, RXRB, RXRG | RXRA 1/4885RXRB 2/4885RXRG 3/4885 |
| US-20090203720-A1 | Methods for inhibiting cell growth | CSNK1G1, CSNK1A1, CSNK2A1 | RXRA 23/4885RXRB 29/4885RXRG 27/4885 |
| US-11690832-B2 | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones | RXRA, RXRB, RXRG | RXRA 1/4885RXRB 2/4885RXRG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.